ReP USP - Resultado da busca

Artigo de periodico
Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparison of ponatinib versus imatinib (2025)
Ashaye, Ajibade; Shi, Ling; Aldoss, Ibrahim; Montesinos, Pau; Vachhani, Pankit; Rocha, Vanderson Geraldo ; Papayannidis, Cristina; Leonard, Jessica T; Baer, Maria R; Ribera, Jose-Maria
Source: Cancer medicine. Unidade: FM
Subjects: LEUCEMIA MIELOIDE AGUDA, SINAIS E SINTOMAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ASHAYE, Ajibade et al. Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparison of ponatinib versus imatinib. Cancer medicine, v. 14, n. 7, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/84773. Acesso em: 29 abr. 2026.
APA
Ashaye, A., Shi, L., Aldoss, I., Montesinos, P., Vachhani, P., Rocha, V. G., et al. (2025). Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparison of ponatinib versus imatinib. Cancer medicine, 14( 7). doi:10.1002/cam4.70780
NLM
Ashaye A, Shi L, Aldoss I, Montesinos P, Vachhani P, Rocha VG, Papayannidis C, Leonard JT, Baer MR, Ribera J-M. Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparison of ponatinib versus imatinib [Internet]. Cancer medicine. 2025 ; 14( 7):[citado 2026 abr. 29 ] Available from: https://observatorio.fm.usp.br/handle/OPI/84773
Vancouver
Ashaye A, Shi L, Aldoss I, Montesinos P, Vachhani P, Rocha VG, Papayannidis C, Leonard JT, Baer MR, Ribera J-M. Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparison of ponatinib versus imatinib [Internet]. Cancer medicine. 2025 ; 14( 7):[citado 2026 abr. 29 ] Available from: https://observatorio.fm.usp.br/handle/OPI/84773
Artigo de periodico
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial (2025)
Ashaye, Ajibade; Shi, Ling; Aldoss, Ibrahim; Montesinos, Pau; Vachhani, Pankit; Rocha, Vanderson Geraldo ; Papayannidis, Cristina; Leonard, Jessica T.; Baer, Maria R.; Ribera, Jose-Maria
Source: Leukemia. Unidade: FM
Subjects: LEUCEMIA, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ASHAYE, Ajibade et al. Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial. Leukemia, v. 39, n. 6, p. 1342-1350, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/87063. Acesso em: 29 abr. 2026.
APA
Ashaye, A., Shi, L., Aldoss, I., Montesinos, P., Vachhani, P., Rocha, V. G., et al. (2025). Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial. Leukemia, 39( 6), 1342-1350. doi:10.1038/s41375-025-02608-4
NLM
Ashaye A, Shi L, Aldoss I, Montesinos P, Vachhani P, Rocha VG, Papayannidis C, Leonard JT, Baer MR, Ribera J-M. Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial [Internet]. Leukemia. 2025 ; 39( 6): 1342-1350.[citado 2026 abr. 29 ] Available from: https://observatorio.fm.usp.br/handle/OPI/87063
Vancouver
Ashaye A, Shi L, Aldoss I, Montesinos P, Vachhani P, Rocha VG, Papayannidis C, Leonard JT, Baer MR, Ribera J-M. Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial [Internet]. Leukemia. 2025 ; 39( 6): 1342-1350.[citado 2026 abr. 29 ] Available from: https://observatorio.fm.usp.br/handle/OPI/87063
Artigo de periodico
Immunophenotype of acute lymphoblastic leukemia in minorities- analysis from the SEER database (2022)
Quiroz, Elisa ; Venkateswaran, Aparajit Ram; Nelson, Rebecca; Aldoss, Ibrahim; Pullarkat, Vinod; Rego, Eduardo Magalhães ; Marcucci, Guido; Douer, Dan
Source: Hematological oncology. Unidades: FM, FO
Subjects: FATORES DE RISCO, LEUCEMIA, CRIANÇAS, SOBREVIDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
QUIROZ, Elisa et al. Immunophenotype of acute lymphoblastic leukemia in minorities- analysis from the SEER database. Hematological oncology, v. 40, n. 1, p. 105-110, 2022Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/50430. Acesso em: 29 abr. 2026.
APA
Quiroz, E., Venkateswaran, A. R., Nelson, R., Aldoss, I., Pullarkat, V., Rego, E. M., et al. (2022). Immunophenotype of acute lymphoblastic leukemia in minorities- analysis from the SEER database. Hematological oncology, 40( 1), 105-110. doi:10.1002/hon.2945
NLM
Quiroz E, Venkateswaran AR, Nelson R, Aldoss I, Pullarkat V, Rego EM, Marcucci G, Douer D. Immunophenotype of acute lymphoblastic leukemia in minorities- analysis from the SEER database [Internet]. Hematological oncology. 2022 ; 40( 1): 105-110.[citado 2026 abr. 29 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50430
Vancouver
Quiroz E, Venkateswaran AR, Nelson R, Aldoss I, Pullarkat V, Rego EM, Marcucci G, Douer D. Immunophenotype of acute lymphoblastic leukemia in minorities- analysis from the SEER database [Internet]. Hematological oncology. 2022 ; 40( 1): 105-110.[citado 2026 abr. 29 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50430

USP Schools

ReP

Filtros

Authors

Subjects

Funding Agencies